114 strains isolated by blood cultures and transtracheal aspirations were typed: serotypes 3 and 4 were largely predominant and a 14-valent vaccine (1, 2, 3, 4, 6, 8, 9, 12, 14, 19, 23, 25, 51, 56) should cover 67 % of these strains and protect 53 % of our patients because the efficacy of the vaccine is evaluated at 80 %. A controlled clinical trial seems to be necessary. We did not isolate any penicillin-resistant strain but 14 % of our strains were resistant to tetracycline.
View Article and Find Full Text PDF